Burger line Burger line Burger line
Logo Logo Logo
Burger line Burger line Burger line
Sign in
Sign in

Gilead, Galapagos’ filgotinib succeeds in PhII ankylosing spondylitis trial

A mid-stage trial assessing Gilead and Galapagos’ JAK 1 inhibitor filgotinib in ankylosing spondylitis has hit its targets.

In the Phase II TORTUGA study, patients treated with filgotinib achieved significantly greater improvements in AS Disease Activity Score (ASDAS), the primary endpoint, at Week 12, with a mean change from baseline of -1.5 versus -0.6 for those treated with placebo.

Also, more patients receiving filgotinib achieved an ASAS20 response compared to those treated with placebo, with the results showing 76% versus 40%.


People with ankylosing spondylitis face serious pain and disability, and, too often, their disease does not respond adequately to existing therapies," said John McHutchison, chief scientific officer and head of R&D at Gilead.

"These data are encouraging, suggesting filgotinib has the potential to play an important role in addressing this medical need."

Dr Walid Abi-Saab, Galapagos’ chief medical officer, said in the trial filgotinib showed “strong activity across a wide range of parameters relevant for ankylosing spondylitis” and was well also tolerated, “which reinforces previous findings about the activity and tolerability profile of filgotinib in multiple inflammatory conditions”.

7th September 2018


0
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote

We use "cookies*  to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:

Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services.
Keeping track of your specified preferences. You may set your preferences through Your Account..
Keeping track of items stored in your shopping basket and personal cabinet.
Conducting research and diagnostics to improve ChemDiv’s content, products, and services.
Delivering content, including ads, relevant to your interests on ChemDiv’s site
Reporting. This allows us to measure and analyse the performance of our services.

By  cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.

Accept all cookies